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Abstract,  Betaglycan, also known as the TGF-/3 type 
III receptor,  is a membrane-anchored proteoglycan that 
presents TGF-/3 to the type II signaling receptor, a 
transmembrane  serine/threonine kinase.  The betagly- 
can extracellular region, which can be shed by cells 
into the medium,  contains a NH2-terminal domain 
related to endoglin and a COOH-terminal domain 
related to uromodulin,  sperm receptors Zp2 and 3, 
and pancreatic secretory granule GP-2 protein.  We 
identified residues Ser  535 and Ser  ~  in the uromodulin- 
related region as the glycosaminoglycan (GAG) attach- 
ment sites. Their mutation to alanine prevents GAG 
attachment but does not interfere with betaglycan sta- 
bility or ability to bind and present TGF-~ to receptor 
II.  Using a panel of deletion mutants,  we found that 
TGF-/~ binds to the NH2-terminal endoglin-related re- 
gion of betaglycan. The remainder of the extracellular 
domain and the cytoplasmic domain are not required 
for presentation of TGF-/~ to receptor II; however, 
membrane anchorage is required.  Soluble betaglycan 
can bind TGF-/3 but does not enhance binding to 
membrane receptors.  In fact, recombinant soluble be- 
taglycan acts as potent inhibitor of TGF-/3 binding to 
membrane receptors and blocks TGF-/3 action,  this 
effect being particularly pronounced with the TGF-/~2 
isoform. The results suggest that release of betaglycan 
into the medium converts this enhancer of TGF-/3 ac- 
tion into a TGF-/3 antagonist. 
T 
He. binding of some cytokines to their signaling recep- 
tors is modulated by accessory receptors. A case in 
point is the binding of TGF-/3 which is assisted by be- 
taglycan,  a membrane-anchored proteoglycan also known as 
the TGF-/3 type III receptor (L6pez-CasiUas  et al.,  1991, 
1993; Wang et al., 1991). TGF-/3  and related cytokines signal 
through  complexes of two distantly  related  transmembrane 
protein serine/threonine  kinases known as receptors I and II 
(Attisano et al., 1992,  1993; Ebner et al., 1993; Estevez et 
al., 1993; Franz6n et al., 1993; Lin and Lodish, 1993; Lin 
et al.,  1992;  Massagu6,  1992;  Mathews and Vale, 1991). 
When expressed alone,  the type I  receptors cannot bind 
ligand,  and the TGF-/~ type II receptor has low affinity for 
TGF-/31 and no affinity  for TGF-/~2. When expressed to- 
gether,  receptors I and  II bind TGF-/~I with high  affinity 
(KD '~ 10-" M), forming a signaling receptor complex, but 
still bind TGF-/32 with low affinity (KD >  10  -9 M) (Attisano 
et al.,  1993; Franz6n  et al.,  1993; Wrana et al.,  1992). 
These limitations  in ligand-binding  ability  can be over- 
come by the action of betaglycan.  When expressed alone or 
purified  from tissue,  betaglycan binds all TGF-/~ isoforms 
with relatively high affinity (KD "~ 10  -1° M) (Andres  et al., 
1991; Massagu6 et al., 1990). In the presence of TGF-#, beta 
glycan on the cell surface associates with the signaling recep- 
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tors (L6pez-Casillas  et al.,  1993; Moustakas et al.,  1993). 
Receptor II binds TGF-8 tethered to membrane betaglycan 
better than it binds TGF-fl free in the medium, and forms a 
stable ternary complex with TGF-~ and betaglycan (L6pez- 
Casillas et al., 1993). Betaglycan is thought to be displaced 
from this complex by receptor I as it becomes available on 
the cell  surface.  As a  result,  betaglycan action  increases 
binding of'rGF-fl to its signaling receptors. This positive ac- 
tion is particularly  evident with TGF-82, an isoform that has 
low affinity for receptors I and II in the absence of betagly- 
can. Various cell lines that do not express betaglycan are less 
sensitive to TGF-/~2 than they are to TGF-/~I (Cbeifetz et al., 
1990;  Ohta et al.,  1987),  and gain  sensitivity  to TGF-J32 
when  transfected  with betaglycan  (L6pez-Casillas  et al., 
1993). Membrane betaglycan is therefore considered a posi- 
tive regulator of TGF-fl access to signaling  receptors. 
The deduced primary  structure of betaglycan reveals  a 
853-amino acid precursor protein with a large extracellular 
domain (L6pez-Casillas  et al.,  1991; Moren et al.,  1992; 
Wang et al.,  1991). This  domain bears no resemblance to 
those of receptors I and II, which are short and contain char- 
acteristic  cysteine  arrangements  (Attisano  et  al.,  1993; 
Childs et al., 1993; Ebner et al., 1993; Franztn et al., 1993; 
Lin et al.,  1992).  The extracellular  domain of betaglycan 
contains heparan sulfate and chondroitin  sulfate glycosami- 
noglycan  (GAG)  t chains.  Betaglycan binds TGF-/~ through 
1. Abbreviation used in this paper:  GAG, glycosaminoglycan. 
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din,  1988),  and  can  bind  basic  fibroblast  growth  factor 
(bFGF) through the heparan sulfate chains  (Andres  et al., 
1992).  The  extracellular  domain is  followed by  a  single 
transmembrane segment and a short cytoplasmic region with 
no discernable  signaling  structure. 
Betaglycan contains regions of similarity to other proteins 
(see Fig.  1). In the NH2-terminal region,  as well as in the 
transmembrane  and cytoplasmic regions,  it  shows amino 
acid sequence similarity to endoglin (Ltpez-Casillas et ai., 
1991;  Wang et  ai.,  1991).  Endoglin  is  a  disulfide-linked 
homodimeric membrane glycoprotein from endothelial cells 
(Gougos and Letarte,  1990) that binds TGF-/~I and ~3 but 
not TGF-~2 (Cheifetz  et al.,  1992). The second half of the 
betaglycan extracellular domain resembles various proteins 
of diverse function (Bork and Sander, 1992). These proteins 
include the kidney-derived urinary protein, uromodulin, the 
sperm  receptors  Zp2  and Zp3,  and the major pancreatic 
secretory  granule  membrane protein GP-2.  In betaglycan, 
this domain contains the two serines that most closely fit the 
consensus for GAG chain attachment. 
In addition to existing as a membrane-anchored  form, the 
ectodomain of betaglycan is shed by cells as a soluble form 
into the medium (Andres et al., 1989; L6pez-Casillas  et al., 
1991).  Although one function of membrane-anchored  be- 
taglycan is to present TGF-D to signaling receptors, the func- 
tion of the soluble form and the participation of the various 
structural  domains of betaglycan  in  these  functions  have 
been unknown.  The present studies address these questions 
with  the  use of mutant  versions  of betaglycan  that lack 
specific  extracellular  segments,  GAG  attachment  sites,  a 
membrane anchor  or a  cytoplasmic domain.  Analysis  of 
these betaglycan  mutants has allowed identification  of the 
TGF-/~-binding region and GAG attachment sites,  and indi- 
cates  that the uromodulin-related  region  is dispensable  for 
ligand binding and presentation to signaling receptors.  Fur- 
thermore, the results show that betaglycan devoid of its mem- 
brane anchor inhibits "rGF-~ binding to cell surface recep- 
tors  and prevents  TGF-/3 action.  Based  on these  results, 
betaglycan is identified as a dual regulator of TGF-/~ access 
to signaling  receptors. 
Materials and Methods 
Construction and Expression of  Mutant 
Betaglycan cDNAs 
The rat betaglycan eDNA containing a  human c-myc  epitope sequence 
(L6pez-Casillas  et al., 1993) was used as the template for all mutant con- 
structs. The nncleotide base pair and amino acid sequence numbering is as 
in the wild-type betnglycan sequences (L6pex-Casillas et ai., 1991) and dis- 
regards the bases/residues added by the c-myc epitope.  To render the AfllII 
site at bp 929 unique in the parental plasmid, the AflllI site located in the 
pGEM-4Z vector backbone was eliminated by AflIH digestion,  mung bean 
nuclease trimming and self  ligation. DNA manipulations were done accord- 
ing to  standard procedures  (Sambrook et ai.,  1989)  and reagents:  en- 
donucleases (Boehringer-Maanheim Corp., Indianapolis,  IN or Bcthesda 
Research Laboratories,  Gaithersburg, MD), DNA polymerase Klenow frag- 
ment (Bochringer-Mannheim), mung bean nuclease (Pharmacia LKB Bio- 
technology, Piscataway, NJ), T4 DNA ligase (Boehringer-Mannheim), and 
competent E. coli HB101 cells (Bethesda Research Laboratories). All con- 
structs were confirmed by sequencing  (USB Sequenase  Kit). 
The specific constructs were obtained as follows. AI: self ligation of the 
large DNA fragment resulting from digestion  with StuI (at bp 462) and 
AflIII (at bp 929) repaired with Klenow fragment. A2: self ligation of the 
large  DNA  fragment resulting from  digestion  with AflHI  (at  hp 929) 
repaired with Klenow  fragment, followed by digestion  with Xhol (at bp 
1829) trimmed with mung bean nuclease; in addition, this manipulation in- 
troduces a Trp at position 200. A3: self ligation of the large DNA fragment 
resulting from digestion with XhoI (at bp 1829) and NcoI (at bp 2677) and 
trimming with mung bean nuclease;  in addition, this manipulation in- 
troduces an Arg at position 499. A5: self  ligation of the large DNA fragment 
resulting from digestion with AflHI (at bp 929) and BclI (at bp 1188) and 
repair with Klenow fragment; in addition, this manipulation introduces  a 
Trp at position 200.  A6: as previously  described (L6pez-Casillas  et al., 
1993).  AS: annealed 5'CCGGCAACTGGGT3'  and 5'GATCACCCAGTT- 
GCCGG3' oligonncleotides  were inserted into the large DNA fragment that 
results from digestion with StuI (at bp 462) and BclI (at bp 1188); in addi- 
tion, this manipulation introduces a Gly at position 45. A9: self ligatinn of 
the large DNA fragment resulting from digestion with EcoRV (at bp 1559) 
and BcLI (at bp 1188) repaired with Klenow fragment. A 10: self ligation 
of the large DNA fragment resulting from digestion  with EcoRV  (at bp 
1559) and NcoI (at bp 2677) repaired with Klenow fragment. Atail: a syn- 
thetic double-stranded 100-bp long oligomer encoding the last 4 residues 
of the ectodomain and the complete transmembrane  region followed by Asp- 
Lys-Lys-Stop, contained NcoI and AvrII sites which were used for insertion 
at the same sites  in betaglycan eDNA,  replacing  the original sequences 
comprised between them. In addition to deleting the cytoplasmic taft, these 
changes created unique HpaI and ClaI sites flanking the transmembrane re- 
gion. $535A,  $546A,  and gag- were created by site directed mutagenesis 
using a PCR strategy, as previously  described (Wrana et al.,  1992).  LS, 
LSgag-, and SS were created by the insertion of an annealed pair of oligo- 
nucleotides  encoding a stop codon at the NcoI site (bp 2677) for the long 
forms,  or at the SaiI site (bp 1870) for the short form.  The gag- mutant 
plasmid was used as the template for the LSgag- construct. In addition, a 
hexa-histidine  sequence was engineered before the stop codon in the long 
soluble forms in order to facilitate the purification  of their products. 
For expression in COS-1 cells, betaglycan cDNA inserts were transferred 
from pGEM-4Z to the pCMV5 mammalian expression vector (Andersson 
et al., 1989) using the flanking EcoRI and HindRI sites. Transient transfec- 
tions were done by the diethylaminoethyl-dextran  method (Seed and Arulfo, 
1987) and assayed 48-72 h later. 
Cell Surface Biotinylation 
Cell monolayers were labeled with sulfosuccinimidyl 6-(biotinoamido)  hex- 
anoate (NHS-LC-biotin, a membrane-impermeable biotinylation reagent, 
Pierce Chem. Co., Rockford, IL) as previously described (Ltpez-Casillas 
et al.,  1993).  Labeled products were displayed  by immunoprecipitation 
from cell lysates  with the anti-myc  epitope monoclonai antibody 9El0 
(Evan et al.,  1985), followed by SDS-PAGE, electroblotting,  and probing 
with peroxidase-conjugated  streptavidin  as previously  described (L6pez- 
Casillas et ai.,  1993). 
TGF-13 Receptor Assays 
TGF-~ and -~2 from porcine platelets (R & D Systems, Inc., Minneapolis, 
MN) were labeled with ~25I  as previously described (Cheifetz et al., 1990). 
Cell surface TGF-~ receptor binding  assays and affinity-labeling assays were 
done as previously described (Massagut, 1987). Where indicated,  labeled 
receptors were immunoprecipitated  from cell lysates with the anti-myc anti- 
body 9El0 (Evan et al.,  1985), or with the anti-HAl epitope monoclonal 
antibody 12CA5 (Meloche et al.,  1992) as previously  described (Ltpez- 
Casillas et al., 1993). For affinity-labeling of soluble receptors, conditioned 
media received Triton-X 100 to a final concentration of 0.05 %, and was in- 
cubated with the indicated concentration n5I-TGF-/~  for 2-3 h at 4°C.  Di- 
succinimidyl suberate (Pierce Chem. Co.) dissolved at 10 mg/ml in DMSO 
was added to a final concentration of 0.1 mg/ml, and incubation continued 
for another 15 rain. The cross-linker was then quenched by adding glycine 
(pH 7.5) to a final concentration of 10 mM, and the reaction mixture was 
immediately mixed with SDS-PAGE sample buffer, boiled, and separated 
in a 7 % polyacrylamide  gel. The region of the gel containing the free radio- 
labeled ligand was removed before autoradingraphy. 
For treatment of betaglycan with chnndroitinase or heparitinase,  lysates 
from affinity-labeled  cells were immunoprecipitated with antibody 9El0 
and the immune complexes were collected with protein-G Sepharose beads. 
After the regular detergent washings,  the beads were washed once with 
digestion  buffer (10 mM Tris-Cl pH 7.5; 50 mM sodium acetate pH 7.5; 
2.5 mM calcium chloride; 0.1% Triton X-100; 0.01% BSA; 10/zg/ml leupep- 
tin; 10/~g/ml antipain; 100 izg/ml benzamidine hydrochloride;  50 pg/ml 
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mM PMSF and then re,  suspended in 0.1 ml of digestion buffer containing 
either no enzymes or 100 mU of chondroitinase ABC (ICN Biochemicals, 
Costa Mesa, CA) alone or together with 20 mU of hepafitinase (ICN Bio- 
chemicals).  These samples were incubated for 12 h at 370C. Incubations 
were stopped by the addition of SDS-PAGE  sample buffer and boiling. The 
products resulting from these treatments were separated in a 6% polyacryl- 
amide gel and revealed by autoradiography. 
Growth Inhibition Assay 
For growth inhibition assays, MvlLu cells (CCL64, ATCC) were seeded in 
minimal essential medium supplemented with non-essential amino acids 
and 0.2 % FBS, at 30,000 cells/cm  2 in 24-well clusters, l~l-iododeoxyuridine 
incorporation into DNA was measured as previously described (Cbeifetz 
et al.,  1990). 
Baculoviral Betaglycan 
The insert in the pCMV5 subclone of the LS construct was transferred to 
the pVLI392 plasmid using the NotI and XbaI sites. Cotran~sfection  of Sf21 
insect  cells  with  the  pVLI392  subclone  of the  LS  construct  and  the 
BaculoGold Viral DNA, as well as the single plaque purification of the re- 
suiting recombinant clones, were carded out as described in the BaculoGold 
Transfection Kit (Pharmigen). Additional amplification and expression of 
the baculoviral strain expressing LS was carried out with SI9 cells, 
Media conditioned by St9 cells was collected 2-3 datter infection with 
either the AcNPV wild-type baculovirus or the recombinant strain express- 
ing the betaglycan LS construct. Before being used in TGF-/~-binding  assays 
and growth inhibition assays, the media were dialyzed (SpectraJFor 6 mem- 
brane; 50,000 dalton cut-off) at 4"C against two changes of minimal essen- 
tial medium supplemented with non-essential amino acids. Samples used 
for growth inhibition were supplemented with 0.2% FBS and those used in 
binding assays received a 1/10 vol of I0 x binding buffer (Massagu~, 1987). 
The amount of soluble betaglycan in the samples was quantitated by West- 
ern  blot  analysis  using  antiserum  raised  against  bacterially  expressed 
betaglycan ectodomaln  (Ltpez-Casillas  et al.,  1993), and  using known 
amounts of this protein as a standard. The various dilutions of media con- 
raining baculoviral betaglycan were made in media conditioned by St9 ceils 
infected with wild-type baculovirus, which served as a negative control. 
Results 
To determine the functional properties of various regions in 
betaglycan, we modified the rat eDNA (Ltpez-Casillas et 
al., 1991) to generate a panel of betaglycan mutants with de- 
letions  of the  extracellular  endoglin-related domain,  the 
uromodulin-related domain, the membrane anchor or the cy- 
toplasmic domain.  We constructed additional mutants in 
which one or both putative GAG attachment sites were al- 
tered by single codon substitutions. To facilitate the isolation 
and visualization of all betaglycan forms with a common an- 
tibody,  all  constructs  included  a  sequence  encoding  the 
human c-myc epitope that is recognized by monoclonal anti- 
body 9El0 (Evans et al.,  1985).  This epitope tag was en- 
gineered six amino acids downstream of the putative signal 
peptide cleavage site. The ligand-binding properties of myc- 
tagged betaglycan are indistinguishable from those of wild- 
type betaglycan (L6pez-Casillas et al., 1993).  The structure 
of the most relevant betaglycan mutants studied are shown 
schematically in Fig.  1. 
Identification of Glycosaminoglycan Attachment Sites 
Betaglycan (Ltpez-CasiUas et al.,  1991; Wang et al.,  1991) 
contains 6  serine-glycine sequences of which only See  35- 
Gly and Se¢~-Gly are surrounded by acidic residues, mak- 
ing them the most likely sites for GAG chain attachment 
(Bourdon et al., 1987). We mutated either one (in $535A or 
Figure 1. Betaglycan mutants. The various betaglycan constructs 
analyzed in this study are presented schematically,  along with their 
TGF-/~-binding activity. The  amino  acid  positions deleted or 
modified are indicated in parentheses. Flanking the uromodulin- 
related domain there are regions (non-s~ed boxes) without 
similarity to known proteins. The first three cysteines within the 
uromodulin-related domain  delimit  a  short  central  region  of 
similarity to endoglin. The GAG chain attachment sites, at serines 
535 and 546, are indicated. 
$546A)  or both [in BG(gag-)] of these serines to alanine, 
and transiently expressed these constructs in COSA  cells. 
Cells were afffinity-labeled by incubation with 12~I-TGF-~I 
and cross-linking with disuccinimidyl suberate.  Detergent 
lysates from these cells were separated by gel electrophoresis 
and the labeled receptors revealed by autoradiography. 
The proteogly,  can form of betaglycan typically migrates as 
a  broad species above  200 kD, and its core lacking GAG 
chains migrates as a doublet at ~130 kD (Fig. 2 A; Andres 
et al., 1991; l.,tpez-Casillas et al., 1991). Mutation of either 
serine yielded proteoglycan forms of faster electrophoretic 
migration (Fig. 2) and increased the proportion of core de- 
void of GAG chains, the latter effect being more pronounced 
in the $535A  mutant (Fig. 2 A). Mutatioii of both seri0es 
completely  abolished  the  addition  of GAG  chains  (lane 
gag-,  Fig.  2 A).  The same effect was observed When ~e 
double mutant BG(gag-) was stably expressed in ~F~ skel- 
etal rat myoblasts (not shown). These results identified  ~ser- 
ines 535 and 546 as the sites for GAG attachment, and sug- 
gested that betaglycan is heterogeneously glycosylated with 
some molecules containing only one GAG chain. 
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are the GAG attachment sites. 
COS-1 cells were transiently 
transfected with the indicated 
mutant betaglyean vectors or 
the  empty vector  (pCMI~), 
and then affinity labeled with 
100 pM  of 125I-TGF-/31. La- 
beled products were subjected 
directly to SDS-PAGE and au- 
toradiography in A. In B, they 
were immunoprecipitated  with 
the antibody 9El0 and then in- 
cubated,  as  indicated,  with 
buffer  alone, chondroitinase 
ABC, or chondroitinase plus 
heparitinase. Incubations,  car- 
ried out as described in Mate- 
rials and Methods, were ter- 
minated  by heating  the samples 
in SDS-PAGE buffer. The re- 
suiting  digestion products 
were subjected  directly  to SDS- 
PAGE and  autoradiography. 
Fully glycosylated  betaglycans 
(  Proteoglycans) and their GAG- 
less cores (Cores) are identi- 
fied  by  their  characteristic 
mobility. The size and mobil- 
ity of protein standards are in- 
dicated in kilodaltons (kDa). 
To determine the type of GAG chains that were attached 
to these two sites, affinity labeled wild-type and mutant be- 
taglycan forms were immunoprecipitated and subjected to 
digestion with chondroitinase and heparitinase.  Complete 
removal of GAG chains from wild-type betaglycan required 
digestion with both enzymes (Fig. 2 B), confirming the pres- 
ence of both heparan sulfate and chondroitin sulfate chains 
(Segarini and Seyedin, 1988; Cheifetz et al., 1988a; L6pez- 
Casillas et al., 1991). Chondroitinase alone was sufficient to 
remove all GAG chains from BG(S535A) but had little effect 
on BG(S546A)  (Fig. 2 B). Heparitinase was required for full 
removal of GAG chains from BG(S546A)  (Fig. 2 B). These 
results indicated that betaglycan expressed in COS cells car- 
ries heparan sulfate attached primarily to Ser  ~35 and chon- 
droitin sulfate attached to Ser  ~. 
The concentration of 125I-TGF-/~l (100 pM) used in these 
binding assays is close to the Kv value of betaglycan (1-4 × 
10  -1° M;  Massagu~ et al.,  1990).  Therefore, these assays 
Should reveal any gross alteration of the binding affinity of 
betaglycan caused by the mutations.  The overall level of 
ligand binding (not shown) and affinity-labeling intensity 
(Fig, 2) of betaglycan lacking GAG chains were similar to 
those of the proteoglycan form,  indicating that the GAG 
chains do not have a  major effect on TGF-~I binding to 
membrane-anchored betaglycan. This result agrees with the 
observation that cells deficient in GAG biosynthetic pathways 
express betaglycan as a core devoid of GAG chains but capa- 
ble of binding TGF-B (Cheifetz and Massagu6,  1989). 
TGF-[3 Binds to the Endoglin-related, NHrTerrninal 
Domain of  Betaglycan 
To  identify the TGF-13-binding region,  betaglycan cDNA 
constructs harboring deletions that removed various portions 
of the extracellular domain were transiently transfected in 
COS-1 cells. Expression of these products on the cell surface 
was  confirmed by  cell  surface biotinylation using  sulfo- 
NHS-biotin (Staros,  1982),  followed by immunoprecipita- 
tion of cell lysates with 9E10 antibody and visualization of 
electrophoretically  separated  proteins  with  streptavidin- 
coupled chemiluminescence (Fig. 3,4). 
The TGF-/5-binding  activity of these mutants was deter- 
mined in binding assays and in afffinity-labeled assays, and 
is summarized in Fig. 1 with representative examples shown 
in Fig. 3 B.  Deletion of the extracellular COOH-terminal 
half downstream of Ile  '10, such  as  in BGA3  and BG~10 
(Fig. 3 B), did not cause any gross alteration in the ability 
to bind  12SI-TGF-/31 or 82.  These two mutant betaglycan 
forms yielded affinity-labeled  products of the expected size, 
and minor products of approximately twice this size (Fig. 3 
B). These minor products might represent internally cross- 
linked betaglycan dimers (Massagu~, 1985). 
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TGF-# binding activity of be- 
taglyean mutants. COS-1 cells 
were  transiently  transfected 
with the indicated betaglycan 
constructs or the empty vector 
(pCMI,~). Parallel cultures of 
transfectants  were  surface- 
labeled  by  biotinylation  (A) 
or  affinity labeled  with  100 
pM I~I-TGF-/~I (B).  Cell ly- 
sates were immunoprecipitated 
with  antibody  9El0,  and the 
immunoprecipitates  analyzed 
by SDS-PAGE and visualized 
by streptavidin-coupled chemi- 
luminescence (A) or autoradi- 
ography (B). 
Deletion of segments upstream to I]~  10 yielded products 
unable to bind Iz~I-TGF-/31 or if2 (Fig.  3 B). The segments 
removed by these mutations (see Fig.  1) included the NH2- 
terminal endogiin-related region (deleted in 48) and an adja- 
cent region with no similarity to any known protein (deleted 
in  z~2). Each  of a  series  of smaller  subdomain  deletions 
(A1, A5, 46, and 49) affecting these regions also eliminated 
TGF-B binding.  These results indicated that the NH2-termi- 
hal half of the betaglycan extracellular domain including the 
endogiin-related  domain contains the TGF-B-binding site. 
Cells expressing  wild-type betaglycan produced equiva- 
lent proportions  of proteoglycan form and  GAG-less core 
(Fig. 3 A; Andres et al.,  1991; L6pez-Casillas et al.,  1991). 
The  GAG-less  core  from  this  source labeled poorly  with 
lz~I-TGF-B1 (compare the proteogiycan forms with the core 
forms in the WT lanes of Fig.  3, A and B).  However, the 
results with the BG(gag-) mutants (see below) and endoge- 
nous betaglycan in  CHO cells deficient in  GAG synthesis 
(Cheifetz and Massagu6,  1989) argue that the binding activ- 
ity of GAG-less betagiycan is similar to that of the proteogiy- 
can form.  Limitations  in the ability of COS cells to com- 
pletely fold and glycosylate all the overexpressed betaglycan 
may explain the high levels of GAG-less core present in cells 
transfected with wild-type betagiycan, and the low-binding 
activity of this core form. 
Deletion  mutants  BG(43)  and  (410)  which  lack  the 
COOH-terminal half of the extracellular domain including 
the two GAG attachment  sites  (Fig.  1),  yielded GAG-less 
products of 75 and 60 kD,  respectively (Fig.  3 A),  as ex- 
pected. Unexpectedly, various deletions in the NH2-tenninal 
half that spared the GAG attachment sites also yielded pre- 
dominantly GAG-less forms [BG(A1),  (A2) and (A5), Fig. 3 
A; BG(46), (A8) and (49), not shown]. This suggested that 
deletions in the NH2-terminal region interfere with the use 
of betaglycan as a substrate for GAG chain attachment,  ow- 
ing perhaps  to misfolding of these mutant forms. 
The TGF-{3  Binding Domain Is Sufficient to 
Support Association of  Membrane Betaglycan with the 
Type H Receptor 
In  the presence  of TGF-/~,  betaglycan associates with  the 
type II receptor, T/SR-II, forming a ternary complex, and we 
have  previously  shown  that  the  binding-defective  mutant 
BG(A6) does not associate with T/3R-II  (l.xipez-Casillas  et 
al.,  1993). To determine whether regions in membrane be- 
taglycan other than the TGF-/5 binding domain were required 
for its association with T/~R-II,  COS-I  cells were cotrans- 
letted with betagiycan constructs of interest together with 
T/SR-II tagged with the influenza virus hemagglutinin  HAl 
epitope  (L6pez-Casillas  et  al.,  1993).  The  cotransfected 
cells were affinity labeled with  Iz~I-TGF-/31 or/~2  and im- 
munopreeipitated  with  anti-HAl  antibody.  This  antibody 
does not precipitate  betaglycan expressed alone in  COS-I 
cells (L6pez-Casillas et al., 1993). Betaglycan mutants lack- 
ing  all  extracellular  regions  outside  the  TGF-/3-binding 
domain,  or  lacking  the  cytoplasmic  region  were  able  to 
associate  with  T~R-II,  as  determined  by  their  ability  to 
coprecipitate with this receptor (Fig. 4).  The mutants also 
retained the ability to enhance the binding of Iz~I-TGF-/32 to 
T/3R-II (Fig. 4), a previously described property of wild-type 
betagiycan (L6pez-Casillas et al.,  1993). These results indi- 
cated that the "l'GF-~-binding  domain of membrane-anchored 
betaglycan is sufficient for formation of a ternary complex 
with TGF-~ and TBR-II and for enhancement of TGF-/5 bind- 
ing to this receptor. 
In these experiments, the amount of label associated with 
TjSR-II was lower than the amount of label associated with 
the copreeipitating betaglycan. It is not possible to draw any 
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between betaglycan and  the 
TGF-B type II receptor. COS-1 
cells were cotransfected with 
the indicated betaglycan mu- 
tants  or  the  empty  vector 
(pCMVS) and a HA1 epitope 
tagged TGF-fl  type II receptor 
vector. Lysates  flora cells  affin- 
ity-labeled with 100 pM 125I- 
TGF-/~I or 100 pM t25I-TGF- 
B2 were immunoprecipitated 
with  the  anti-HA1 antibody 
and analyzed by SDS-PAGE 
and autoradiography.  The im- 
munoprecipitated TGF-fl  type 
II receptor (TBR-II/HA) and 
coprecipitated molecules are 
indicated. Migration  of molec- 
ular weight standards (kDa) is 
shown. 
conclusions from these data about the stoichiometry of the 
complex because  the relative efficiency of the  t25I-TGF-B 
cross-linking reactions with betaglycan and TBR-II is not 
known. 
Binding Activity of  Soluble Betaglycan 
Secreted versions of betaglycan were created by engineering 
a stop codon at appropriate sites in the eDNA. A long sol- 
uble betaglycan form, BG(LS), was generated by placing a 
stop codon just upstream of the transmembrane region (Fig. 
1). A GAG-less version of this form, BG(LS gag-) was sim- 
ilarly constructed using the BG(gag-) cDNA. When trans- 
fected into COS-1  ceils, these constructs yielded secreted 
products of the predicted size, as determined by immunopre- 
cipitation or Western blotting of samples from the conditioned 
media (not shown),  mI-TGF-B1 binding and cross-linking 
to these products in solution, followed  by gel electrophoresis 
and autoradiography, revealed strong TGF.-~-binding activi~ 
(Fig. 5). Similar results were obtained if the sec~.t~! Ero- 
teins were isolated with 9E10 antibody bound to, protein-G 
Sepharose heads and then tested for ligand-binding activity 
(not shown)~, ,- 
A shorter: form of soluble betaglycan, BG(SS), containing 
the TGF-fl-binding domain and lacking most of the uromod- 
ulin-related domain was gencyated by inserting.# stop codon 
at position 515 (Fig~ 1). :~then a6sayed in~edj'ately after col- 
lection 0f~he cogditiqn#d media, ~  binding activity 9f this 
form expressed in COS-1 cell~ was comparable to that of the 
larger soluble forms (Fig, 5)., However, the stability of these 
proteins differed greatly. When stored at 4°C, BG(SS) lost 
all TGF-/$-bjndjng  activity (as determined by binding and 
cross-linking assays) within the first 2 d of storage whereas 
BG(LS) and (LS gag-) showed no significant loss of activity 
aJ~t~ .~ months of storage at 4°C under sterile conditions 
(data not shown). The preparations of BG(SS) progressively 
aggregated form~n&  glisulfxde-linked complexes,  as  deter- 
Figure  5. Soluble  betaglycan  forms bind TGF-~. Samples  of freshly 
collected media from COS-1 ceUs  expressing  the indicated  beta#y- 
can constructs or the empty vector (pCMV3) were affinity-labeled 
with 370 pM 125I-TGF-fll and analyzed by SDS-PAGE and autora- 
diography. 
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binding  to  MvlLu  cells  by 
soluble betaglycan. (A) Media 
conditioned  by  Sf9  insect 
cells, infected with wild-type 
baculovirus (mock) or a  re- 
combinant baculovirus  con- 
taining the BG(LS) construct, 
were  analyzed  by  affinity 
labeling.  (B)  MvlLu  cells 
were incubated with 25  pM 
t2SI-TGF-fll  (open symbols) 
or 25 pM 125I-TGF-f12 (closed 
symbols) in  the  presence of 
Sf9-conditioned  medium con- 
taining the indicated concen- 
trations of soluble betaglycan. 
The betaglycan concentration 
was determined as described 
under Materials and Methods. 
The various dilutions of  media 
containing  baculoviral be- 
taglycan were made in media 
conditioned by Sf9 cells in- 
fected with wild-type baculo- 
virus, which therefore served 
as a negative control. At the 
end  of the  incubation, cell 
monolayers were washed with binding buffer, and the associated radioactivity was determined. The amount of bound TGF-fl is plotted 
relative to the amount bound in ceil monolayers that received no exogenous betaglycan. 
mined by Western blotting of samples electrophoresed in the 
absence of reductant (data not shown). A shorter form cre- 
ated by introduction of  a stop codon at position 410 was more 
stable than BG(SS) but in contrast to its membrane-anchored 
counterpart, this form showed markedly decreased TGF-fl- 
binding activity (data not shown). These results confirmed 
that the  NH2-terminal half of betaglycan is  sufficient for 
TGF-fl binding, but removal of segments outside this region 
may severely decrease the stability or binding activity of sol- 
uble betaglycan. 
Inhibition of TGF-{3 Binding to Membrane Receptors 
by Soluble Betaglycan 
Cells release soluble betaglycan by proteolytic cleavage at a 
site near the transmembrane region (Andres et al.,  1989; 
L6pez-Casillas et al., 1991). Since this form is similar in size 
to BG(LS), we used this recombinant protein to study the 
ability of soluble betaglycan to affect TGF-/~ binding to cell 
surface receptors.  The BG(LS)  cDNA,  subcloned into a 
baculovirus vector and expressed in insect Sf9 ceils, yielded 
high levels of secreted protein capable of binding TGF-fl 
(Fig.  6  A).  The baculoviral BG(LS) was devoid of GAG 
chains  (Fig.  6  A).  When  added to  MvlLu cell  cultures, 
medium conditioned by  Sf9  cells  infected with wild-type 
baculovirus, induced a loss of GAG chains from cell surface 
betaglycan (data not shown, but see Fig. 7 A). This result 
suggested that a glycosaminidase  present in these preparations 
was responsible for the removal of GAG chains from baculo- 
viral betaglycan. Nevertheless, the stability and TGF-fl-bind- 
ing activity of the GAG-less BG(LS) produced in St9 cells 
was similar to that of BG(LS) produced in COS-1 cells. 
The ability of soluble betaglycan to affect the TGF-fl inter- 
action with cell surface receptors was tested using MvlLu 
mink lung epithelial cells that are very sensitive to growth 
inhibition by TGF-/~ and have well characterized TGF-B re- 
ceptors (Boyd and Massagut,  1989;  Laiho et al.,  1990a,b; 
Wrana et al., 1992). Addition of soluble betaglycan from in- 
sect cells during incubation of MvlLu ceils with 25 pM x25I- 
TGF-~I or/32 strongly inhibited binding of these ligands to 
cell surface receptors (Fig. 6 B). The various dilutions of 
media containing baculoviral betaglycan were made in media 
conditioned by Sf9 cells infected with wild-type baculovirus, 
which served as a negative control. The betaglycan concen- 
tration required for a 50% of inhibition of binding was 0.3 
nM  for ~25I-TGF-~l and  ~50  pM  for ~2sI-TGF-fl2. At the 
highest concentrations tested (5.2 nM), betaglycan reduced 
~zSI-TGF-~ binding  by  80%  and  ~25I-TGF-f12 binding  by 
>98% (Fig. 6 B). This difference between isoforms is con- 
sistent with the higher affinity of betaglycan for TGF-fl2 
(Andres et al.,  1991; Mitchell et al.,  1992;  Segarini et al., 
1987). 
A similar inhibitory effect of soluble betaglycan was ob- 
served when TGF-fl interaction with cell surface receptors 
was determined by receptor affinity-labeling. Soluble beta- 
glycan inhibited the labeling of type I and II receptors with 
an IDso of 0.3 nM when 25 pM I~I-TGF-fll was used as the 
ligand and '~80 pM with 25 pM mI-TGF-/~2 as the ligand 
(Fig.  7).  Complete  inhibition of the  ~Zq-TGF-fl2 binding 
was observed  with  1 nM  soluble betaglycan, and nearly 
complete inhibition of ~2q-TGF-/31 binding with 5 nM sol- 
uble betaglycan. 
Soluble Betaglycan Acts as a TGF-B Antagonist 
To test whether addition of soluble betaglycan would inhibit 
Ldpez-Casillas  et al. Regulation of IU1~{3  Access to Receptors  563 Figure  7. Inhibition of TGF-B  binding to signaling receptors by soluble betaglycan. MvlLu cells were incubated with 25 pM 125I-TGF-/~l 
or 25 pM tzsI-'I'GF-/T2  in the presence of the indicated concentrations of baculoviral soluble betnglycan, as described in Fig, 6. After wash- 
ing unbound ligand, cell monolayers were incubated with the bifunctional crosslinker (disuccinimidyl suberate), and the resulting attinity- 
labeled products were subjected to SDS-PAGE and revealed by autoradiography (.4). The characteristic mobilities of the MvlLu TGF-B 
receptors (BG, BG core, TI~R-II, and gBR-I) are indicated. The relatively high proportion of GAG-less BG core seen in this experiment 
is due to glycosaminidase activity present in the St9 conditioned media (see text). This activity does not affect the labeling of the other 
receptors. The relative labeling intensity of the TGF-/~  type I receptor band (B) and type II receptor band (C) were quantitated using a 
Phosphorimager (Molecular Dynamics, Sunnyvale, CA). Certain betaglycan comentrations caused an apparently complete inhibition of 
receptor labeling with t2SI-TGF-ff2  as detected by autoradiography. However, the higher sensitivity of the Phosphorimnger revealed that 
the level of inhibition in some of these conditions was still partial (compare A with B and C). (open symbols) ~2SI-TGF-BI;  (closed sym- 
bols) t2SI-TGF-/~2. 
the biological activity of TGF-/~, we determined its effect on 
the growth inhibitory response of MvlLu cells to TGF-/3 as 
measured  by  t25I-deoxyuridine  incorporation  into  DNA 
(Laiho et al., 1990a). Addition of 5.8 nM soluble baculoviral 
betaglycan decreased the growth inhibitory potency of TGF- 
B2 approximately 20-fold, from EDs0 =  0.5 pM to EDso =  10 
pM (Fig. 8 A). Soluble betaglycan reduced the effect  of TGF- 
B2 in a concentration-dependent manner (Fig. 8 B), corre- 
lating closely with the inhibition of TGF-/32 binding to re- 
ceptors. For example, a  reduction of the effective TGF-/T2 
concentration from 5 pM to 0.5 pM, or 90%, would decrease 
the growth inhibitory effect  by 50% (Fig. 8 A). Indeed, addi- 
tion of 0.6 nM soluble betaglycan, which reduced TGF-/52 
binding to cell surface receptors by ,,,90% (see Figs. 6 and 
7), decreased the growth inhibitory effect of 5 pM TGF-/32 
by 50% (Fig. 8 B). As expected from its lower potency as 
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Figure 8. Inhibition of TGF-/3 
action by soluble betaglycan. 
MvlLu cells  were incubated 
for 24  h  with  the  indicated 
concentrations of TGF-/32  and 
Sf9  conditioned  media,  and 
allowed  to  incorporate  ]25I- 
deoxyuridine into DNA dur- 
ing the last 4 h of this incuba- 
tion. Before their use in these 
assays, conditioned  media from 
SD cells were dialyzed against 
standard growth inhibition as- 
say media. In A, incubations 
were done in standard media 
(open circles), dialyzed con- 
ditioned media from SD cells 
infected with wild-type bacu- 
lovirus  (closed circles),  or 
dialyzed  conditioned  media 
from Sf9 cells containing 5.8 
nM soluble baculoviral beta- 
glycan (open squares). In B, 
cells were incubated  with 5 pM 
TGF-~52 added in dialyzed conditioned media from betaglycan-secreting Sf9 cells mixed with control conditioned media (Sf9 cells infected 
with wild-type baculovirus) to achieve the indicated final concentrations of soluble baculoviral betaglycan. Data are average from triplicate 
assays, +standard  errors. 
an inhibitor of TGF-/31 binding, soluble betaglycan added at 
5.8 nM decreased the growth inhibitory potency of TGF-/5'I 
only ~50%  (data not shown). 
Discussion 
Betaglycan is a structurally complex membrane proteogly- 
can, and the present studies investigate the functional role of 
its various domains. One of the most significant outcomes of 
this work is the finding that whereas membrane-anchored 
betaglycan acts as an enhancer of TGF-/3 action, the released 
form of betaglycan acts as a TGF-/3 antagonist by preventing 
its access to cell surface receptors. 
Glycosaminoglycan Attachment Sites in Betaglycan 
The present studies confirm the earlier prediction (Ltpez- 
Casillas et al.,  1991) that Ser  535 and Ser  ~  are the GAG chain 
attachment sites in betaglycan. These residues are located in 
Ser-Gly sequences surrounded by acidic residues, which is 
consensual  for  GAG  chain  attachment  (Bourdon  et  al., 
1987). Mutation of either serine to alanine decreases the ex- 
tent of betaglycan glycosylation, and mutation of both ser- 
ines prevents GAG chain attachment completely. 
In most cell lines examined including COS cells, betagly- 
can contains both heparan sulfate and chondroitin sulfate 
chains  as  determined by digestion  with  heparitinase  and 
chondroitinase (Segarini and Seyedin, 1988; Cheifetz et al., 
1988a; Ltpez-Casillas et al., 1991). Mutant betaglycan with 
Set  ~  as the sole GAG attachment site was completely con- 
verted to GAG-less core by chondroitinase alone, indicating 
that Ser  ~  carries only chondroitin sulfate chains. Betagly- 
can with  Ser  53~  as  the  sole GAG attachment site  showed 
some susceptibility to digestion by chondroitinase and more 
to heparitinase, indicating that Ser  53~ carries predominantly 
heparan sulfate chains. 
The GAG-less betaglycan cores obtained by enzymatic 
removal of the GAG chains or by mutational elimination of 
the GAG attachment sites are heterogeneous in size. The het- 
erogeneity is not eliminated by enzymatic or chemical treat- 
merits that remove other carbohydrate chains from the GAG- 
less core (Cheifetz et al., 1988a). This heterogeneity is also 
observed by surface-biotinylation ofbetaglycan core (this re- 
port). We have found no evidence for alternative betaglycan 
transcripts.  Therefore, the basis  for this heterogeneity re- 
mains unknown. 
The NH2-Terminal Endoglin-related 
Domain in Membrane Betaglycan Binds and 
Presents TGF-~ 
The NH2-terminal region of betaglycan shows  only 28% 
amino acid sequence similarity to the corresponding region 
of  endoglin,  another  TGF-/3-binding  protein  (Bork  and 
Sander,  1992; Cheifetz et al.,  1992). Our deletion analysis 
confirmed that in betaglycan this  region,  with a  COOH- 
terminal  extension,  mediates  TGF-/3  binding,  and  other 
regions are not critical for this  function. Furthermore, in 
membrane-anchored betaglycan,  the  NH2-terminal  endo- 
glin-related region is also sufficient to present bound TGF-/3 
to the signaling type II receptor. The GAG chains, the uro- 
modulin-related region which contains an additional short 
segment of similarity to endoglin, and the cytoplasmic do- 
main which shows the highest level of sequence identity to 
endoglin (l_,tpez-Casillas  et ai., 1991; Wang et al., 1991; see 
Fig.  1), are dispensable for TGF-/~ presentation to the sig- 
naling  receptor.  However, membrane  anchorage  of beta- 
glycan seems critical for complex formation with receptor H 
and enhancement of ligand binding to this receptor. This 
conclusion is based on the observed inability of soluble beta- 
glycan to perform these functions. 
The preference of receptor II for TGF-B tethered to be- 
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mobilization of the ligand at the cell surface. However, even 
accounting for the higher affinity of betaglycan for TGF-fl2, 
this model seems too simple to explain the much stronger en- 
hancement of TGF-fl2 binding to receptor II by betaglycan. 
It is possible that TGF-B bound to betaglycan adopts a con- 
formation that is more favorable for recognition by receptor 
II; unbound TGF-B1 might approximate such conformation 
better than unbound TGF-B2. 
The present results predict that the "l'GF-fl-binding site in 
endoglin is located in the NH2-terminal betaglycan-related 
domain.  The limited amino acid sequence similarity be- 
tween these domains in betaglycan and endoglin correlates 
with a markedly different  ability to bind TGF-/Z2. Betaglycan 
binds TGF-B2 somewhat better than it binds TGF-B1 or B3 
whereas endoglin does not bind TGF-B2  (Cheifetz et al., 
1992). 
The Uromodulin-related  Domain Is Not Critical for 
Interaction with TGF-[3 or Its Signaling Receptors 
The region in betaglycan that is related to the proteins uro- 
modulin, pancreatic zymogen granule protein GP-2,  and 
sperm receptors Zp2 and Zp3, is characterized by a certain 
pattern  of cysteines, hydrophobic,  polar  or  turn-forming 
residues that are thought to generate related three-dimen- 
sional structures (Bork and Sander, 1992). The GAG attach- 
ment sites in betaglycan, serines 535 and 546, reside in this 
region.  Except for the ability of the heparan sulfate GAG 
chains to bind bFGF (Andres et al., 1992),  the function of 
this region remains unknown. Its deletion does not have a 
major effect on the TGF-/~ binding or presentation activities 
of betaglycan, although soluble betaglycan devoid of most of 
this region is unstable. It is noteworthy that all known pro- 
teins containing the uromodulin-related domain are either 
membrane proteins that yield soluble forms (betaglycan, 
uromodulin, and GP-2)  (Andres et al.,  1989;  Hoops and 
Rindler, 1991; Rindler et al., 1990),  or proteins that reside 
in the pericellular environment (Zp2 and 3) (Saling, 1991). 
This raises the possibility that the function of the uromod- 
ulin-related domain is to control the stability, diffusion, or 
interactions of these proteins in the periceUular environ- 
ment. However, our truncated betaglycan form might be un- 
stable for other reasons, and the present evidence is therefore 
insufficient  to demonstrate a primary role of  the uromodulin- 
related domain in the stabilization of these proteins. 
Our results are in contrast to those reported by Fukushima 
et al. (1993) who localized TGF-fl binding to a segment of 
the uromodulin-related domain. However, their studies used 
bacterially  expressed  fragments  of betaglycan  that  bind 
TGF-/~ with a much lower affinity than we observed for the 
NH2-termin~  TGF-/3-binding  domain expressed  in mam- 
malian cells. 
The Released Form of  Betaglycan Is a 
TGF-fl Antagonist 
Several signaling cytokine receptors  exist in soluble forms 
that are generated by cleavage of the membrane form or by 
exclusion of membrane and cytoplasmic-coding exons from 
their transcripts "(Elders and Riordan, 1991). Some of these 
soluble forms may act as ligand antagonists, as has been 
shown with the TNF, IL-1, and IL-4 receptors (Howard et 
al., 1993; Loetscher et al., 1991; Maliszewski et al., 1990) 
whereas others such as the soluble CNTF receptor c~ still 
contribute positively to the assembly of a signaling receptor 
complex (Davis et al., 1993).  The present results show that 
in contrast to membrane betaglycan, soluble betaglycan in- 
hibits TGF-/~ binding to membrane receptors and acts as a 
TGF-/$ antagonist. Thus, betaglycan can play a dual role as 
a modulator of TGF-fl access to signaling receptors. 
Membrane anchorage is critical for the role of betaglycan 
as a regulator of TGF-/~ access to the signaling receptors. 
Membrane-anchored betaglycan  binds TGF-fl independently 
from the signaling receptors, and can form a ternary com- 
plex with receptor II through bound TGF-/~. This phenome- 
non, observed in all cell lines examined, is thought to reflect 
a process of TGF-/3 presentation and transfer to the signaling 
receptor (L6pez-Casillas et al.,  1993).  Membrane betagly- 
can enhances TGF-/3 binding to the signaling receptors and 
cell responsiveness to TGF-/~, particularly to TGF-B2,  sug- 
gesting that the signaling receptor binds TGF-fl tethered to 
membrane betaglycan better than it binds TGF-~ free in the 
medium (L6pez-Casillas et al., 1993).  The soluble form of 
betaglycan can  also  bind  TGF-fl  independently of other 
receptors, however it does not form stable associations with 
membrane-anchored receptors.  Rather, soluble betaglycan 
interferes with TGF-/$ access to these receptors and therefore 
inhibits TGF-/3 action. The ratio between soluble and mem- 
brane-anchored forms of betaglycan in the cell's periphery 
is probably an important determinant of TGF-/3 activity. It 
will be important to investigate whether the release of beta- 
glycan ectodomain is a regulated process. 
Given its high affinity and specificity for TGF-/3, its nature 
as a physiological TGF-/$ receptor, and its potency as an in- 
hibitor of TGF-fl action, soluble betaglycan may prove ad- 
vantageous as an anti-TGF-/3 agent in vivo. TGF-/~ is a regu- 
lator of cell proliferation, differentiation and extracellular 
matrix  accumulation  in  many  tissues  (Massagn6,  1990; 
Roberts and Sporn, 1990). Its excess is thought to contribute 
to pathological processes of  inflammation, immune response 
(Kulkarni et al., 1993; Shull et al., 1992; Wahl, 1992),  and 
fibrotic disorders (Border and Ruoslahti, 1992; Sellheyer et 
al., 1993). In animal model systems, administration of TGF-fl 
antibodies or decorin, a small extracellular matrix proteo- 
glycan that binds TGF-/~, show beneficial effects in some 
of these disorders (Border et al., 1992; Border et al., 1990; 
Yamaguchi  et al.,  1990).  Betaglycan could be useful for 
similar purposes. In addition to being able to bind TGF-/~ 
with a Ko in the subnanomolar range, betaglycan can act 
selectively  on  different TGF-B  isoforms.  TGF-B2  has  a 
higher affinity for betaglycan than TGF-B1, and a higher de- 
pendence on betaglycan for access to the signaling receptors 
(Andres et al.,  1991; L6pez-Casillas et al.,  1993;  Mitchell 
et al., 1992; Segarini et al., 1987). TGF-/32 might therefore 
be the isoform most susceptible to the action of betaglycan 
in vivo, and the other isoforms might rank according to their 
binding affinity (Cheifetz et al.,  1988b,  1990). 
Our present work, using cell lines in culture, has revealed 
contrasting functions for soluble and membrane betaglycan 
as a modulator of "rGF-~ access to its signaling receptors. 
Experiments in animal model systems will be needed to es- 
tablish whether or not betaglycan possesses  similar dual 
functionality  in vivo, and to prove its usefulness as a modula- 
tor of TGF-# activity. 
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